Robert B Nussenblatt1, Richard W J Lee2, Emily Chew3, Lai Wei3, Baoying Liu3, H Nida Sen3, Andrew D Dick2, Frederick L Ferris3. 1. National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: DrBob@nei.nih.gov. 2. National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and University College London Institute of Ophthalmology, University Hospitals Bristol National Health Service, Foundation Trust, and University of Bristol, Bristol, England, United Kingdom. 3. National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
PURPOSE: To describe the immune alterations associated with age-related macular degeneration (AMD); and, based on these findings, to offer an approach to possibly prevent the expression of late disease. DESIGN: Perspective. METHODS: Review of the existing literature dealing with epidemiology, models, and immunologic findings in patients. RESULTS: Significant genetic associations have been identified and reported, but environmentally induced (including epigenetic) changes are also an important consideration. Immune alterations include a strong interleukin 17 family signature as well as marked expression of these molecules in the eye. Oxidative stress as well as other homeostatic altering mechanisms occur throughout life. With this immune dysregulation there is a rationale for considering immunotherapy. Indeed, immunotherapy has been shown to affect the late stages of AMD. CONCLUSION: Immune dysregulation appears to be an underlying alteration in AMD, as in other diseases thought to be degenerative and attributable to aging. Para-inflammation and immunosenescence may importantly contribute to the development of disease. The role of complement factor H still needs to be better defined, but in light of its association with ocular inflammatory conditions such as sarcoidosis, it does not appear to be unique to AMD but rather may be a marker for retinal pigment epithelium function. With the strong interleukin 17 family signature and the need to treat early on in the disease process, oral tolerance may be considered to prevent disease progression. Published by Elsevier Inc.
PURPOSE: To describe the immune alterations associated with age-related macular degeneration (AMD); and, based on these findings, to offer an approach to possibly prevent the expression of late disease. DESIGN: Perspective. METHODS: Review of the existing literature dealing with epidemiology, models, and immunologic findings in patients. RESULTS: Significant genetic associations have been identified and reported, but environmentally induced (including epigenetic) changes are also an important consideration. Immune alterations include a strong interleukin 17 family signature as well as marked expression of these molecules in the eye. Oxidative stress as well as other homeostatic altering mechanisms occur throughout life. With this immune dysregulation there is a rationale for considering immunotherapy. Indeed, immunotherapy has been shown to affect the late stages of AMD. CONCLUSION: Immune dysregulation appears to be an underlying alteration in AMD, as in other diseases thought to be degenerative and attributable to aging. Para-inflammation and immunosenescence may importantly contribute to the development of disease. The role of complement factor H still needs to be better defined, but in light of its association with ocular inflammatory conditions such as sarcoidosis, it does not appear to be unique to AMD but rather may be a marker for retinal pigment epithelium function. With the strong interleukin 17 family signature and the need to treat early on in the disease process, oral tolerance may be considered to prevent disease progression. Published by Elsevier Inc.
Authors: Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Lai Wei; Baoying Liu; Jingsheng Tuo; Defen Shen; Ping Chen; Zhiyu Li; Xunxian Liu; Jia Ni; Pradeep Dagur; H Nida Sen; Shayma Jawad; Diamond Ling; Stanley Park; Sagarika Chakrabarty; Catherine Meyerle; Elvira Agron; Frederick L Ferris; Emily Y Chew; J Philip McCoy; Emily Blum; Peter J Francis; Michael L Klein; Robyn H Guymer; Paul N Baird; Chi-Chao Chan; Robert B Nussenblatt Journal: Cell Rep Date: 2012-11-21 Impact factor: 9.423
Authors: Richard W J Lee; Lauren P Schewitz; Lindsay B Nicholson; Colin M Dayan; Andrew D Dick Journal: Invest Ophthalmol Vis Sci Date: 2009-04-01 Impact factor: 4.799
Authors: Baoying Liu; Lai Wei; Catherine Meyerle; Jingsheng Tuo; H Nida Sen; Zhiyu Li; Sagarika Chakrabarty; Elvira Agron; Chi-Chao Chan; Michael L Klein; Emily Chew; Frederick Ferris; Robert B Nussenblatt Journal: J Transl Med Date: 2011-07-15 Impact factor: 5.531
Authors: M Cristina Kenney; Marilyn Chwa; Shari R Atilano; Janelle M Pavlis; Payam Falatoonzadeh; Claudio Ramirez; Deepika Malik; Tiffany Hsu; Grace Woo; Kyaw Soe; Anthony B Nesburn; David S Boyer; Baruch D Kuppermann; S Michal Jazwinski; Michael V Miceli; Douglas C Wallace; Nitin Udar Journal: PLoS One Date: 2013-01-24 Impact factor: 3.240
Authors: Fernando Cruz-Guilloty; Ali M Saeed; Jose J Echegaray; Stephanie Duffort; Asha Ballmick; Yaohong Tan; Michel Betancourt; Eduardo Viteri; Ghansham C Ramkhellawan; Eric Ewald; William Feuer; Deqiang Huang; Rong Wen; Li Hong; Hua Wang; James M Laird; Abdoulaye Sene; Rajendra S Apte; Robert G Salomon; Joe G Hollyfield; Victor L Perez Journal: Int J Inflam Date: 2013-03-07
Authors: Gavin W Roddy; Robert H Rosa; Kimberly B Viker; Bradley H Holman; Cheryl R Hann; Anuradha Krishnan; Gregory J Gores; Sophie J Bakri; Michael P Fautsch Journal: Curr Eye Res Date: 2019-12-02 Impact factor: 2.424
Authors: Jacob K Sterling; Bailey Baumann; Sierra Foshe; Andrew Voigt; Samyuktha Guttha; Ahab Alnemri; Sam J McCright; Mingyao Li; Randy J Zauhar; Sandra R Montezuma; Rebecca J Kapphahn; Venkata R M Chavali; David A Hill; Deborah A Ferrington; Dwight Stambolian; Robert F Mullins; David Merrick; Joshua L Dunaief Journal: Cell Rep Date: 2022-06-14 Impact factor: 9.995